Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$2.30
$0.04(2.94%)
At close: 4:00 PM EDT
$2.30
$0.04(2.94%)
Day’s Range― - ―
52-Week Range$1.05 - $3.58
Previous CloseN/A
Volume17.83K
Average Volume (3M)134.92K
Market Cap
$8.62M
Enterprise Value$6.28
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding7,200,378
10 Day Avg. Volume171,979
30 Day Avg. Volume134,916
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageVery low leverage limits interest burden and reduces balance-sheet stress while the company funds clinical development. This gives management greater flexibility than a highly indebted biotech, although continued losses still require careful capital planning.
Improving Loss And Cash-burn TrendThe narrower 2025 losses and lower cash burn indicate some expense discipline and could extend operating runway if sustained. This does not establish profitability, but it improves the efficiency of advancing the pipeline and moderates near-term funding pressure.
Merger Adds Funding And Precision-medicine CapabilitiesThe planned Scipher combination brings committed financing, an AI-guided clinical strategy, and access to PrismRA precision-medicine capabilities. A stated runway into late 2028 could support trial execution and preserve development capacity across multiple indications.
Bears Say
No Demonstrated Product RevenueThe absence of product revenue means the company has not yet validated commercial demand or created a self-sustaining operating model. Future value therefore depends heavily on clinical progress, regulatory outcomes, and eventual partnering or commercialization success.
Persistent Cash Burn Requires External FinancingOngoing negative operating and free cash flow means internal operations cannot fund research and clinical programs. Continued reliance on equity, partnerships, or other financing exposes the company to funding availability and potential shareholder dilution over the next several quarters.
Chemomab Holders Face Merger DilutionChemomab shareholders will receive a minority share of the combined company, reducing their proportionate ownership of future economics. Although the merger may add capabilities and funding, the ownership split limits Chemomab holders’ direct participation in the combined platform’s upside.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.05 and its highest was $3.58 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $8.62M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 35 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Aug 19, 2026. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.147.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,200,378 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 9.424%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$5.00
▲(117.39% Upside)